The effect of metformin in diabetic patients with kidney disease

Completed

• Conditions: Kidney disease; Type 2 diabetes; Renal and Urogenital - Kidney disease; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12611000893909
• Lead Sponsor: Prof Richard Day

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-08-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

Kidney disease, type 2 diabetes

Exclusion Criteria

Significant cardiac disease, any hypoxic condition, alcohol abuse, history of lactic acidosis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Accumulation of metformin in the body assessed by assaying metformin concentrations in plasma[Weekly for 6 weeks.]

Secondary Outcome Measures

Name	Time	Method
Relationship between metformin concentration, glycaemic control and lactate concentration. Glycaemic control is assessed by self-monitored fasting blood sugar levels, fructosamine and HbA1c test.[Baseline, and at 6 weeks after intervention]